NexPlasmaGen Inc. is a Canadian company applying cold plasma technologies to the treatment of cancer, striving to improve patients outcomes.
Our first cold plasma technology, the Convertible Plasma Jet (CPJ), has been developed in collaboration with academic and health care partners since many years. Several papers and conferences have been published on the CPJ.
The CPJ device has successfully completed a preclinical trial program in vitro and in vivo to demonstrate in mice model that it can kill residual breast cancer cells in the tumor bed after the tumor is removed.
See our Technology and Facts pages to learn more.
We are currently preparing the first in human trials with the CPJ device to demonstrate it can kill residual breast cancer cells in the tumor bed after the tumor is removed.